Results 211 to 220 of about 276,679 (267)

Evolution of hematopoietic stem cell potential from preterm to term neonates. [PDF]

Hemasphere
Quaranta P, Basso-Ricci L, Seffin L, Pacini G, Ronchi A, Crimi R, Fumagalli M, Pietrasanta C, Scala S.   +8 more
europepmc   +1 more source

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation

Clinical Pharmacology &Therapeutics, EarlyView.
The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix, Sam Mostafa, Amin Rostami‐Hodjegan, Thomas M. Polasek, Carl M. J. Kirkpatrick   +4 more
wiley   +1 more source

Pregnancy after hematopoietic stem cell transplant: an international multicenter study. [PDF]

Blood Adv
Salooja N, Eikema DJ, Michonneau D, Tichelli A, Apperley JF, Akhtar S, Bourhis JH, Maertens J, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola A, Schaap N, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak G, Peric Z, Penack O, Schoemans H.   +22 more
europepmc   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

DHX9 sustains hematopoietic stem cell function in cooperation with H3 acetylation. [PDF]

Stem Cell Reports
Shi M, Gao M, Luo H, Wang C, Hu X, Xiong Y, Chen Y, Ren X, Zhu S, Zhu H.   +9 more
europepmc   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Platelet factor 4 regulates hematopoietic stem cell aging. [PDF]

Blood
Zhang S, Ayemoba CE, Di Staulo AM, Joves K, Patel CM, Leung EHW, Bueno MLP, Du X, Poncz M, Ong SG, Nerlov C, Maryanovich M, Chronis C, Pinho S.   +13 more
europepmc   +1 more source

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Busulfan's narrow therapeutic index and high pharmacokinetic (PK) variability warrant investigation of its exposure–toxicity relationship. We retrospectively analyzed 334 pediatric and young adult patients who underwent allogeneic hematopoietic stem cell transplantation at Seoul National University Children's Hospital between 2009 and 2020 and received
Sungyeun Bae, Jung Yoon Choi, Kyung Taek Hong, Bo Kyung Kim, Hyun Jin Park, Kyung‐Sang Yu, Su‐jin Rhee, Hyoung Jin Kang   +7 more
wiley   +1 more source

Bacterial meningoencephalitis following allogeneic hematopoietic stem cell transplantation: A case report and literature review. [PDF]

Exp Ther Med
Shi Y, Han Y, Chen J, Liu H, Zhang X, Song R, Ma X, Feng Q, Wu T.   +8 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source